concerning amid a persistent property crisis and soft domestic consumption. for clues on what the second half of the year could bring, i m joined byjameel ahmad, if you look at this of the 500, and record highs of 35 and those of the types of records that be taking place that cristiano ronaldo would be jealous of mr v catnip it wasn t as us stock markets but those all time highs and bit coin, gold and we should talk about the supercharge as well becoming the largest company in the world market capitalisation were generally speaking, some solid fundamentals despite the policy pretty much generation in the united states and very strong but he pointed out earlier that the biggest question now is the uncertainty around the federal reserve and the central bank and monday will finally begin new interest rates. ~ . ~ will finally begin new interest rates. . ~ , will finally begin new interest rates. ., ~ , ., rates. what you think is going to happen rates. what you think is goin
Pfizer Offers Government A Not-For-Profit Price For Roll-Out Of Its Two-Dose mRNA COVID-19 Vaccine In India
Pfizer logo (Pic Via Wikipedia)
United States (US) based pharmaceutical giant Pfizer said on Thursday (22 April) that it has offered a not-for-profit price for its COVID-19 vaccine to the Indian government and that it is in talks with the administration to deploy its vaccine for the ongoing nationwide inoculation drive, reports
Hindustan Times.
Pfizer in a collaboration with BioNTech has developed a two-dose mRNA vaccine that has been widely used in the US, Europe, Israel and other countries. The Pfizer Covid-19 vaccine has an efficacy of 95 per cent against the disease.
Synopsis
Johnson & Johnson had appealed the 2019 ruling that found the company guilty of negligent marketing and deceptive conduct while supplying thousands of pelvic meshes in Australia.
iStock The risks were known, not insignificant, and on the respondents own admission, could cause significant and serious harm, the judge said in the initial ruling.
An Australian court upheld a landmark class-action lawsuit against Johnson & Johnson for negligent marketing of pelvic mesh implants on Friday, paving the way for thousands of women to receive compensation in a costly setback for the US pharma giant.
Johnson & Johnson had appealed the 2019 ruling that found the company guilty of negligent marketing and deceptive conduct while supplying thousands of pelvic meshes in Australia.